Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States

American Journal of Hematology

Volumn 89, Issue 7, 2014, Pages 714-720

  Gibson, Todd M ^a,f   Engels, Eric A ^a   Clarke, Christina A ^b,c   Lynch, Charles F ^d   Weisenburger, Dennis D ^e   Morton, Lindsay M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY PANCREAS TRANSPLANTATION; LARGE CELL LYMPHOMA; LIVER GRAFT; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; ORGAN TRANSPLANTATION; POPULATION; PRIORITY JOURNAL; RISK FACTOR; STANDARDIZED INCIDENCE RATIO; UNITED STATES;

ADOLESCENT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84902826618     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23726     Document Type: Article

References (39)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
2. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003;89:1221-1227.
3. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306:1891-1901.
4. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007;370:59-67.
5. Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007;43:2117-2123.
6. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-2831.
7. Villeneuve PJ, Schaubel DE, Fenton SS, et al. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007;7:941-948.
8. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56:155-167.
9. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001;3:60-69.
10. Nalesnik MA. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998;20:325-342.
11. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10:877-886, discussion 886-877.
12. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69:827-833.
13. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998;16:2052-2059.
14. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-968.
15. van Leeuwen MT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009;114:630-637.
16. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011;86:206-209.
17. Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases? Transplantation 2005;79:244-247.
18. Opelz G, Daniel V, Naujokat C, Dohler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009;88:962-967.
19. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: An analysis of the SRTR National Registry Data in the United States. Am J Transplant 2012;12:976-983.
20. Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012;12:682-693.
21. Donnelly LF, Frush DP, Marshall KW, White KS. Lymphoproliferative disorders: CT findings in immunocompromised children. AJR Am J Roentgenol 1998;171:725-731.
22. Lim GY, Newman B, Kurland G, Webber SA. Posttransplantation lymphoproliferative disorder: Manifestations in pediatric thoracic organ recipients. Radiology 2002;222:699-708.
23. Opelz G, Dohle B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004;4:222-230.
24. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
25. Morton LM, Wang SS, Cozen W, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008;112:5150-5160.
26. Clarke CA, Morton LM, Lynch CF, et al. Risk of lymphoma subtypes after solid organ transplantation in the U.S. Br J Cancer 2013;109:280-288.
27. Engels EA, Clarke CA, Pfeiffer RM, et al. Plasma cell neoplasms in US solid organ transplant recipients. Am J Transplant 2013;13:1523-1532.
28. Mbulaiteye SM, Clarke CA, Morton LM, et al. Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol 2013;88:245-250.
29. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654.
30. Vajdic CM, van Leeuwen MT, Turner JJ, et al. No excess risk of follicular lymphoma in kidney transplant and HIV-related immunodeficiency. Int J Cancer 2010;127:2732-2735.
31. Fritz A, Percy C, Jack A, et al., editors. International Classification of Diseases for Oncology, 3rd ed. Geneva: World Health Organization; 2000.
32. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006;6:1111-1131.
33. Breslow N, Day N. The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer;1987.
34. Pierce DA, Preston DL. Joint analysis of site-specific cancer risks for the atomic bomb survivors. Radiat Res 1993;134:134-142.
35. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729.
36. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-1516.
37. Birkeland SA. Chronic antigenic stimulation from the graft as a possible oncogenic factor after renal transplant. Scand J Urol Nephrol 1983;17:355-359.
38. Chadburn A, Suciu-Foca N, Cesarman E, et al. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995;147:1862-1870.
39. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80:1233-1243.